

said inhaler has an internal surface and all or part of said internal surface is a material selected from the group consisting of stainless steel and anodized aluminum.

12. (New) The pressurized metered dose inhaler of Claim 11, wherein said solution further comprises a low-volatility component.

13. (New) The pressurized metered dose inhaler of Claim 12, wherein said low-volatility component is selected from the group consisting of propylene glycol, glycerol, polyethylene glycol, and isopropyl myristate.

14. (New) The pressurized metered dose inhaler of Claim 11, wherein said active ingredient is selected from the group consisting of β 2 agonists, steroids, anticholinergic agents, and mixtures thereof.

15. (New) The pressurized metered dose inhaler of Claim 11, wherein said active ingredient is selected from the group consisting of β -adrenergic agonists, ipratropium bromide, oxitropium bromide, tiotropium bromide, flunisolide, triamcinolone acetonide, fluticasone propionate, mometasone furoate, budesonide, ciclesonide, rofleponide, and epimers thereof.

16. (New) The pressurized metered dose inhaler of Claim 11, wherein said co-solvent is ethanol.

17. (New) The pressurized metered dose inhaler of Claim 11, wherein said propellant is selected from the group consisting of HFA 227, HFA 134a, and mixtures thereof.

18. (New) The pressurized metered dose inhaler of Claim 11, wherein part or all of said internal surface is stainless steel.

19. (New) The pressurized metered dose inhaler of Claim 11, wherein part or all of said internal surface is anodized aluminum.

20. (New) The pressurized metered dose inhaler of Claim 11, wherein said solution further comprises a low-volatility component; said low-volatility component is selected from the group consisting of propylene glycol, glycerol, polyethylene glycol, and isopropyl myristate; said active ingredient is selected from the group consisting of β -adrenergic agonists, ipratropium bromide, oxitropium bromide, tiotropium bromide, flunisolide, triamcinolone acetonide, fluticasone propionate, mometasone furoate, budesonide, ciclesonide, rofleponide, and epimers thereof; said co-solvent is ethanol; said propellant is selected from the group consisting of HFA 227, HFA 134a, and mixtures thereof; and part or all of said internal surface is stainless steel.

21. (New) The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is ipratropium bromide.

22. (New) The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is oxitropium bromide.

23. (New) The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is tiotropium bromide.

24. (New) The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is flunisolide.

25. (New) The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is triamcinolone acetonide.

26. (New) The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is fluticasone propionate.

27. (New) The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is mometasone furoate.

28. (New) The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is budesonide.

29. (New) The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is ciclesonide.

30. (New) The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is rofleponide.

31. (New) The pressurized metered dose inhaler of Claim 11, wherein said solution further comprises a low-volatility component; said low-volatility component is selected from the group consisting of propylene glycol, glycerol, polyethylene glycol, and isopropyl myristate; said active ingredient is selected from the group consisting of β -adrenergic agonists, ipratropium bromide, oxitropium bromide, tiotropium bromide, flunisolide, triamcinolone acetonide, fluticasone propionate, mometasone furoate, budesonide, ciclesonide, rofleponide, and epimers thereof; said co-solvent is ethanol; said propellant is selected from the group consisting of HFA 227, HFA 134a, and mixtures thereof; and part or all of said internal surface is anodized aluminum.

32. (New) The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is ipratropium bromide.

33. (New) The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is oxitropium bromide.

34. (New) The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is tiotropium bromide.

35. (New) The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is flunisolide.

36. (New) The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is triamcinolone acetonide.

37. (New) The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is fluticasone propionate.

38. (New) The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is mometasone furoate.

39. (New) The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is budesonide.

40. (New) The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is ciclesonide.

41. (New) The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is rofleponide.

42. (New) The pressurized metered dose inhaler of Claim 15, wherein said active β -adrenergic agonist is selected from the group consisting of salbutamol, formoterol, salmeterol, and TA 2005.

43. (New) The pressurized metered dose inhaler of Claim 20, wherein said active β -adrenergic agonist is selected from the group consisting of salbutamol, formoterol, salmeterol, and TA 2005.

44. (New) The pressurized metered dose inhaler of Claim 31, wherein said active β -adrenergic agonist is selected from the group consisting of salbutamol, formoterol, salmeterol, and TA 2005.

SUPPORT FOR THE AMENDMENTS

Applicants have canceled Claims 1-10 and added new Claims 11-41. Support for new Claims 11 and 12 can be found in Claim 1 as originally filed. Support for new Claim 13 can be found in Claim 4 as originally filed, and page 7, lines 12-15. Support for new Claim 14 can be found in Claim 2 as originally filed. Support for new Claim 15 can be found in claim 3 as originally filed, and page 8, lines 19-27. Support for new Claim 16 can be found in Claim 5 as originally filed. Support for new Claim 17 can be found in Claim 6 as originally filed. Support for new Claims 18 and 19 can be found in Claim 1 as originally filed. Support for new Claim 20 can be found in Claims 1 and 3-6 as originally filed, and page 7, lines 12-15, and page 8, lines 19-27. Support for new Claims 21-30 and 32-41 can be found in Claim 3 as originally filed. Support for new Claim 31 can be found in Claims 1 and 3-6 as originally filed, and page 7, lines 12-15, and page 8, lines 19-27. Support for Claims 42-44 can be found on page 8, lines 26-28, of the specification.

No new matter has been added. Claims 11-44 are active in this application.